ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma

The ROBUST trial (n=570) did not meet the primary end point with no significant difference in progression free survival (PFS) of lenalidomide plus R-CHOP vs placebo [0.85 (95% CI, 0.63 to 1.14) p=0.29]. 2-year PFS was 67% for R2-CHOP and 64% for placebo/R-CHOP.

Journal of Clinical Oncology